2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.25: Exploring A>I(G) RNA Editing Patterns Linked to Cisplatin Sensitivity in LUAD Patients with Non-Actionable Mutations: Potential Biomarkers for Precision Oncology

PP01.25: Exploring A>I(G) RNA Editing Patterns Linked to Cisplatin Sensitivity in LUAD Patients with Non-Actionable Mutations: Potential Biomarkers for Precision Oncology

Back to course

Pdf Summary

This study by Yanara A. Bernal, Alejandro Blanco, and Ricardo Armisén investigates RNA editing patterns linked to cisplatin sensitivity in lung adenocarcinoma (LUAD) patients who do not have driver or actionable mutations. It highlights the potential of RNA editing biomarkers for precision oncology.<br /><br />AI(G) RNA editing involves the conversion of adenosine to inosine, which is read as guanosine on RNA. This editing mechanism contributes to biological diversity but, when disrupted, is associated with various diseases including cancers. In LUAD, 37.8% of patients lack driver or actionable mutations, leading to limited therapeutic options. Thus, identifying new biomarkers is critical.<br /><br />The study analyzed RNA editing sites in the TCGA and GDSC databases, finding 8,571 shared sites in LUAD cell lines. Thirty sites show differential editing patterns between patients with and without actionable mutations, suggesting these patterns might indicate sensitivity or resistance to cisplatin chemotherapy.<br /><br />One gene of interest is RAC1, which may serve as a prognostic biomarker or a predictor of therapy response due to its association with brain metastasis and poor overall survival in LUAD. The study's methodology included both DNA and RNA sequencing to ensure high-confidence identification of RNA-edited sites.<br /><br />The research posits that RNA editing could represent a novel source of biomarkers for cancer treatment, with RAC1 specifically highlighted for further study to understand its biological significance. The study was funded by several grants and supported by the International Association for the Study of Lung Cancer (IASLC).<br /><br />In conclusion, comprehensive characterization of RNA editing patterns could facilitate the development of predictive biomarkers, aiding clinical decisions in oncology.

Asset Subtitle

Yanara Bernal

Keywords

RNA editing

cisplatin sensitivity

lung adenocarcinoma

LUAD

biomarkers

precision oncology

RAC1

TCGA

GDSC

RNA sequencing